Trial Profile
Phase II trial of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in patients with NSCLC of squamous histology who have progressed on prior therapy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2015
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BIND Therapeutics
- 22 Dec 2014 New trial record
- 19 Nov 2014 This global trial is being planned, according to a BIND Therapeutics media release.